Drreddys Laboratories | RDY - Selling And Administration Expenses


Drreddys Laboratories reported INR28.08B in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
Bayer EUR 4.02B 53M Sep/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Cipla INR 13.25B 101.8M Dec/2025
Corcept Therapeutics USD 142.04M 14.86M Sep/2026
Drreddys Laboratories INR 28.08B 13.61B Sep/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Novartis USD 3.08B 163M Sep/2026
Pacira USD 950.8M 858.99M Sep/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 2.08B 2.04B Sep/2026
Richter Gedeon HUF 57.76B 2.43B Jun/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026